Tabuk Makes MENA Deal For Prestige’s Trastuzumab

Pair Strike Agreement On Rights To Tuznue Biosimilar To Herceptin

Saudi firm Tabuk has struck a deal to sell Prestige BioPharma’s Tuznue trastuzumab biosimilar in the MENA region.

MENA Map At Night
The deal gives Tabuk rights to Prestige’s trastuzumab in the MENA region • Source: Shutterstock

Saudi generics and branded medicines supplier Tabuk Pharmaceuticals has struck a deal with Singapore-based Prestige BioPharma for the right to sell Prestige’s Tuznue (trastuzumab) biosimilar rival to Herceptin in the Middle East and North Africa region.

The licensing and distribution agreement gives Tabuk “exclusive rights to commercialize and distribute Tuznue in the MENA region, leveraging the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business